After a high-profile mention on a popular podcast, prescriptions combining ivermectin with benzimidazole drugs rose sharply among cancer patients, sparking fresh debate about celebrity influence, limited evidence, and patient safety. This article walks through the endorsement, the prescribing surge, what the new study found, and why clinicians and researchers are sounding the alarm.
An actor named specific drugs during a widely watched podcast episode and credited them with dramatic recoveries, saying “all three of them don’t have cancer right now at all.” When pressed on names, he replied, “Ivermectin, fenbendazole.” That exchange reached millions and appears to have had real-world effects on prescribing patterns.
The medications in question are not new: ivermectin treats certain parasitic infections in humans, and fenbendazole is a veterinary benzimidazole used for worms in animals. Some lab and animal studies have hinted at anti-cancer activity, but translating those findings to safe, effective human treatment is a very different prospect.
Researchers mined millions of ambulatory records to see whether doctors were prescribing ivermectin along with a benzimidazole — drugs like albendazole, fenbendazole, mebendazole or thiabendazole — after the podcast aired. They found that overall prescribing roughly doubled, and rates rose about 2½ times among patients listed as having cancer, with larger increases in men, White patients, those aged 18 to 64, and people in southern states.
The analysis did not, however, show whether patients actually took the medicines or whether any health outcomes changed; safety and effectiveness were not measured. The paper is observational, so it cannot prove the celebrity appearance caused the rise in orders, and researchers warned that some prescriptions might have been written but never filled, or that patients could have sought veterinary formulations through nonmedical channels.
Experts caution that the doses which produced effects in lab settings would “typically be considered toxic for humans,” according to Dr. Skyler B. Johnson of the University of Utah Huntsman Cancer Institute. He and others have raised concerns about how ivermectin might interfere with the way the body processes conventional cancer drugs and other medications, creating a risk of harm rather than help.
The lead author addressed the human side of this dynamic directly: “Clinicians talk about how difficult it is when the patient demands or asks for a medication that they really feel passionately might help,” lead author Michelle Rockwell, a health services researcher at Virginia Tech, said in a press release. “And that’s where I think these celebrity influencers really play a big role.” That tension between patient hope and clinical evidence is a constant pressure in oncology clinics.
Limitations in the study include possible misclassification of cancer status and no assessment of whether patients took these agents alongside standard treatments or as substitutes. The researchers also noted the potential for unprescribed purchases from agricultural suppliers, and they emphasized that the prescription signal does not equal demonstrated benefit or safety.
Clinicians and patient advocates uniformly recommend discussing treatment choices with trusted medical providers before starting or stopping therapies. Given the current evidence, experts say clinical trials would be required to establish safety and effectiveness, and taking antiparasitic drugs off-label for cancer remains unproven and potentially dangerous.
